Fresh Tracks Therapeutics, Inc. (FRTX)
USD 0.94
(-0.53%)
USD 0.94
(-0.53%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 8 Million USD | 212.76% |
| 2022 | -7.1 Million USD | 74.49% |
| 2021 | -27.82 Million USD | -196.22% |
| 2020 | -9.39 Million USD | 23.61% |
| 2019 | -12.29 Million USD | -6711.29% |
| 2018 | 186 Thousand USD | -97.47% |
| 2017 | 7.34 Million USD | -10.92% |
| 2016 | 8.24 Million USD | -17.79% |
| 2015 | 10.02 Million USD | 128.16% |
| 2014 | 4.39 Million USD | 188.21% |
| 2013 | -4.98 Million USD | -128.43% |
| 2012 | 17.51 Million USD | -11.3% |
| 2011 | 19.75 Million USD | 824.81% |
| 2010 | -2.72 Million USD | -121.48% |
| 2009 | 12.68 Million USD | 59.45% |
| 2008 | 7.95 Million USD | 44.34% |
| 2007 | 5.51 Million USD | -62.61% |
| 2006 | 14.74 Million USD | 22.8% |
| 2005 | 12 Million USD | -17.48% |
| 2004 | 14.54 Million USD | 80.05% |
| 2003 | 8.07 Million USD | 15.29% |
| 2002 | 7 Million USD | -38.35% |
| 2001 | 11.36 Million USD | 28.86% |
| 2000 | 8.82 Million USD | -24.61% |
| 1999 | 11.7 Million USD | 72.06% |
| 1998 | 6.8 Million USD | -21.84% |
| 1997 | 8.7 Million USD | 19.18% |
| 1996 | 7.3 Million USD | 7.35% |
| 1995 | 6.8 Million USD | 13.33% |
| 1994 | 6 Million USD | 1900.0% |
| 1993 | 300 Thousand USD | 175.0% |
| 1992 | -400 Thousand USD | 33.33% |
| 1991 | -600 Thousand USD | -50.0% |
| 1990 | -400 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 FY | 8 Million USD | 212.76% |
| 2023 Q1 | -1.92 Million USD | -247.21% |
| 2023 Q2 | -556 Thousand USD | 71.15% |
| 2023 Q3 | 7.94 Million USD | 1528.78% |
| 2023 Q4 | - USD | -100.0% |
| 2022 Q2 | 2.45 Million USD | 141.38% |
| 2022 Q3 | -3.07 Million USD | -225.47% |
| 2022 Q4 | -555 Thousand USD | 81.95% |
| 2022 Q1 | -5.92 Million USD | -96.38% |
| 2022 FY | -7.1 Million USD | 74.49% |
| 2021 FY | -27.82 Million USD | -196.22% |
| 2021 Q2 | -8.68 Million USD | -43.94% |
| 2021 Q3 | -10.09 Million USD | -16.15% |
| 2021 Q4 | -3.01 Million USD | 70.12% |
| 2021 Q1 | -6.03 Million USD | -33.16% |
| 2020 Q1 | -1.61 Million USD | 72.85% |
| 2020 FY | -9.39 Million USD | 23.61% |
| 2020 Q3 | -1.13 Million USD | 45.89% |
| 2020 Q2 | -2.1 Million USD | -30.1% |
| 2020 Q4 | -4.53 Million USD | -297.89% |
| 2019 Q3 | -2.15 Million USD | -30.07% |
| 2019 Q1 | -2.52 Million USD | 40.75% |
| 2019 FY | -12.29 Million USD | -6711.29% |
| 2019 Q4 | -5.96 Million USD | -176.69% |
| 2019 Q2 | -1.65 Million USD | 34.47% |
| 2018 Q3 | -4.08 Million USD | -169.12% |
| 2018 FY | 186 Thousand USD | -97.47% |
| 2018 Q4 | -4.26 Million USD | -4.33% |
| 2018 Q2 | -1.51 Million USD | -110.97% |
| 2018 Q1 | -720 Thousand USD | -133.29% |
| 2017 Q1 | 1.89 Million USD | -1.86% |
| 2017 FY | 7.34 Million USD | -10.92% |
| 2017 Q2 | 1.81 Million USD | -4.06% |
| 2017 Q3 | 1.46 Million USD | -19.63% |
| 2017 Q4 | 2.16 Million USD | 47.95% |
| 2016 FY | 8.24 Million USD | -17.79% |
| 2016 Q3 | 1.64 Million USD | -60.0% |
| 2016 Q1 | 4.6 Million USD | 211.91% |
| 2016 Q2 | 4.12 Million USD | -10.47% |
| 2016 Q4 | 1.93 Million USD | 17.16% |
| 2015 Q4 | -4.11 Million USD | -182.0% |
| 2015 FY | 10.02 Million USD | 128.16% |
| 2015 Q1 | 4.94 Million USD | 239.56% |
| 2015 Q2 | 4.17 Million USD | -15.53% |
| 2015 Q3 | 5.01 Million USD | 20.14% |
| 2014 Q4 | 1.45 Million USD | -57.7% |
| 2014 FY | 4.39 Million USD | 188.21% |
| 2014 Q1 | 2.44 Million USD | 25.42% |
| 2014 Q2 | 4.5 Million USD | 84.1% |
| 2014 Q3 | 3.44 Million USD | -23.6% |
| 2013 Q3 | -2.35 Million USD | 3.2% |
| 2013 Q4 | 1.95 Million USD | 182.77% |
| 2013 FY | -4.98 Million USD | -128.43% |
| 2013 Q2 | -2.43 Million USD | -254.7% |
| 2013 Q1 | 1.57 Million USD | -32.13% |
| 2012 Q4 | 2.31 Million USD | 238.2% |
| 2012 Q3 | -1.67 Million USD | -22.66% |
| 2012 Q2 | -1.36 Million USD | -115.22% |
| 2012 Q1 | 8.98 Million USD | 1508.78% |
| 2012 FY | 17.51 Million USD | -11.3% |
| 2011 Q2 | -1.78 Million USD | 14.82% |
| 2011 Q1 | -2.09 Million USD | 75.36% |
| 2011 Q3 | 24.27 Million USD | 1457.72% |
| 2011 Q4 | -638 Thousand USD | -102.63% |
| 2011 FY | 19.75 Million USD | 824.81% |
| 2010 FY | -2.72 Million USD | -121.48% |
| 2010 Q4 | -8.52 Million USD | -16940.0% |
| 2010 Q3 | -50 Thousand USD | 96.31% |
| 2010 Q2 | -1.35 Million USD | -1.04% |
| 2010 Q1 | -1.34 Million USD | -152.52% |
| 2009 Q1 | 2.25 Million USD | -80.26% |
| 2009 Q2 | 3.97 Million USD | 76.8% |
| 2009 Q3 | 3.9 Million USD | -1.89% |
| 2009 FY | 12.68 Million USD | 59.45% |
| 2009 Q4 | 2.55 Million USD | -34.54% |
| 2008 FY | 7.95 Million USD | 44.34% |
| 2008 Q1 | -1.16 Million USD | -109.88% |
| 2008 Q4 | 11.39 Million USD | 708.81% |
| 2008 Q2 | -403 Thousand USD | 65.44% |
| 2008 Q3 | -1.87 Million USD | -364.52% |
| 2007 Q2 | -1.1 Million USD | 58.95% |
| 2007 FY | 5.51 Million USD | -62.61% |
| 2007 Q4 | 11.8 Million USD | 572.96% |
| 2007 Q3 | -2.49 Million USD | -125.88% |
| 2007 Q1 | -2.69 Million USD | -121.97% |
| 2006 FY | 14.74 Million USD | 22.8% |
| 2006 Q4 | 12.25 Million USD | 625.2% |
| 2006 Q3 | -2.33 Million USD | -184.62% |
| 2006 Q2 | 2.75 Million USD | -50.9% |
| 2006 Q1 | 5.61 Million USD | 211.08% |
| 2005 Q4 | 1.8 Million USD | -33.32% |
| 2005 Q3 | 2.7 Million USD | -43.69% |
| 2005 Q2 | 4.8 Million USD | 79.1% |
| 2005 Q1 | 2.68 Million USD | -46.35% |
| 2005 FY | 12 Million USD | -17.48% |
| 2004 Q2 | 5.74 Million USD | 531.51% |
| 2004 Q1 | 909.18 Thousand USD | -46.39% |
| 2004 Q3 | 2.89 Million USD | -49.65% |
| 2004 Q4 | 5 Million USD | 73.06% |
| 2004 FY | 14.54 Million USD | 80.05% |
| 2003 Q4 | 1.69 Million USD | -65.2% |
| 2003 FY | 8.07 Million USD | 15.29% |
| 2003 Q1 | 908.33 Thousand USD | 71.97% |
| 2003 Q2 | 601.19 Thousand USD | -33.81% |
| 2003 Q3 | 4.87 Million USD | 710.58% |
| 2002 Q3 | 2.51 Million USD | 2.95% |
| 2002 FY | 7 Million USD | -38.35% |
| 2002 Q1 | 1.51 Million USD | -68.32% |
| 2002 Q4 | 528.19 Thousand USD | -79.04% |
| 2002 Q2 | 2.44 Million USD | 61.96% |
| 2001 Q4 | 4.77 Million USD | 99.98% |
| 2001 Q1 | 5.41 Million USD | 96.99% |
| 2001 Q2 | 1.77 Million USD | -67.2% |
| 2001 FY | 11.36 Million USD | 28.86% |
| 2001 Q3 | 2.38 Million USD | 34.2% |
| 2000 FY | 8.82 Million USD | -24.61% |
| 2000 Q1 | 1.25 Million USD | -75.36% |
| 2000 Q4 | 2.75 Million USD | 57.13% |
| 2000 Q3 | 1.75 Million USD | -42.8% |
| 2000 Q2 | 3.06 Million USD | 143.62% |
| 1999 Q1 | 3.5 Million USD | 218.18% |
| 1999 Q3 | 1.5 Million USD | -6.25% |
| 1999 Q4 | 5.1 Million USD | 240.0% |
| 1999 FY | 11.7 Million USD | 72.06% |
| 1999 Q2 | 1.6 Million USD | -54.29% |
| 1998 Q2 | 900 Thousand USD | -68.97% |
| 1998 FY | 6.8 Million USD | -21.84% |
| 1998 Q4 | 1.1 Million USD | -42.11% |
| 1998 Q3 | 1.9 Million USD | 111.11% |
| 1998 Q1 | 2.9 Million USD | 16.0% |
| 1997 Q4 | 2.5 Million USD | -34.21% |
| 1997 FY | 8.7 Million USD | 19.18% |
| 1997 Q1 | 1.3 Million USD | -43.48% |
| 1997 Q2 | 1.1 Million USD | -15.38% |
| 1997 Q3 | 3.8 Million USD | 245.45% |
| 1996 FY | 7.3 Million USD | 7.35% |
| 1996 Q4 | 2.3 Million USD | 228.57% |
| 1996 Q3 | 700 Thousand USD | -81.08% |
| 1996 Q2 | 3.7 Million USD | 516.67% |
| 1996 Q1 | 600 Thousand USD | -33.33% |
| 1995 Q4 | 900 Thousand USD | -30.77% |
| 1995 Q2 | 3.7 Million USD | 236.36% |
| 1995 Q1 | 1.1 Million USD | 37.5% |
| 1995 Q3 | 1.3 Million USD | -64.86% |
| 1995 FY | 6.8 Million USD | 13.33% |
| 1994 Q4 | 800 Thousand USD | -50.0% |
| 1994 Q1 | 1.1 Million USD | 121.57% |
| 1994 Q2 | 2.4 Million USD | 118.18% |
| 1994 Q3 | 1.6 Million USD | -33.33% |
| 1994 FY | 6 Million USD | 1900.0% |
| 1993 Q1 | 3.8 Million USD | 322.22% |
| 1993 FY | 300 Thousand USD | 175.0% |
| 1993 Q4 | -5.1 Million USD | -737.5% |
| 1993 Q3 | 800 Thousand USD | -11.11% |
| 1993 Q2 | 900 Thousand USD | -76.32% |
| 1992 Q3 | 900 Thousand USD | 0.0% |
| 1992 FY | -400 Thousand USD | 33.33% |
| 1992 Q1 | 900 Thousand USD | 50.0% |
| 1992 Q2 | 900 Thousand USD | 0.0% |
| 1992 Q4 | 900 Thousand USD | 0.0% |
| 1991 Q3 | 600 Thousand USD | 0.0% |
| 1991 Q4 | 600 Thousand USD | 0.0% |
| 1991 FY | -600 Thousand USD | -50.0% |
| 1991 Q1 | 600 Thousand USD | 20.0% |
| 1991 Q2 | 600 Thousand USD | 0.0% |
| 1990 Q1 | 400 Thousand USD | 0.0% |
| 1990 Q4 | 500 Thousand USD | 0.0% |
| 1990 FY | -400 Thousand USD | 0.0% |
| 1990 Q3 | 500 Thousand USD | 25.0% |
| 1990 Q2 | 400 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| AbCellera Biologics Inc. | 38.02 Million USD | 78.945% |
| Alkermes plc | 1.37 Billion USD | 99.418% |
| Agenus Inc. | 139.61 Million USD | 94.266% |
| Aptorum Group Limited | -1.11 Million USD | 818.228% |
| Ardelyx, Inc. | 106.66 Million USD | 92.494% |
| Dyadic International, Inc. | 922.95 Thousand USD | -767.429% |
| Eton Pharmaceuticals, Inc. | 21.06 Million USD | 61.987% |
| Lantern Pharma Inc. | -174.84 Thousand USD | 4678.965% |
| Inhibikase Therapeutics, Inc. | -13.35 Million USD | 159.935% |
| Novavax, Inc. | 639.93 Million USD | 98.749% |
| Janux Therapeutics, Inc. | -46.83 Million USD | 117.093% |
| Pyxis Oncology, Inc. | -2 Million USD | 500.3% |
| TransCode Therapeutics, Inc. | -516.74 Thousand USD | 1649.31% |
| Ocuphire Pharma, Inc. | 19.04 Million USD | 57.958% |
| Outlook Therapeutics, Inc. | -44.18 Thousand USD | 18218.041% |
| Madrigal Pharmaceuticals, Inc. | -527 Thousand USD | 1619.165% |
| Reviva Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| SELLAS Life Sciences Group, Inc. | - USD | -Infinity% |
| Syros Pharmaceuticals, Inc. | -98.21 Million USD | 108.151% |
| Barinthus Biotherapeutics plc | 802 Thousand USD | -898.254% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 9863.415% |
| Xeris Biopharma Holdings, Inc. | 135.26 Million USD | 94.081% |
| Clearside Biomedical, Inc. | 7.87 Million USD | -1.715% |
| C4 Therapeutics, Inc. | -96.95 Million USD | 108.258% |
| Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | 99.473% |
| AlloVir, Inc. | -398 Thousand USD | 2111.558% |
| Arrowhead Pharmaceuticals, Inc. | 240.73 Million USD | 96.674% |
| VYNE Therapeutics Inc. | 424 Thousand USD | -1788.208% |
| Bicycle Therapeutics plc | -129.52 Million USD | 106.181% |
| BioXcel Therapeutics, Inc. | 120 Thousand USD | -6571.667% |
| ChromaDex Corporation | 50.78 Million USD | 84.234% |
| Chimerix, Inc. | 324 Thousand USD | -2370.988% |
| Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | 125.687% |
| Caribou Biosciences, Inc. | -77.59 Million USD | 110.317% |
| CRISPR Therapeutics AG | 240.95 Million USD | 96.677% |
| Precision BioSciences, Inc. | 40.47 Million USD | 80.218% |
| Fate Therapeutics, Inc. | -98.16 Million USD | 108.156% |
| Fortress Biotech, Inc. | 57.85 Million USD | 86.161% |
| Fortress Biotech, Inc. | 57.85 Million USD | 86.161% |
| HOOKIPA Pharma Inc. | 16.57 Million USD | 51.704% |
| ImmuCell Corporation | 4.39 Million USD | -82.108% |
| IDEAYA Biosciences, Inc. | -106.12 Million USD | 107.544% |
| Immix Biopharma, Inc. | -5468.00 USD | 146515.508% |
| Incyte Corporation | 3.44 Billion USD | 99.767% |
| Innoviva, Inc. | 261.06 Million USD | 96.933% |
| IO Biotech, Inc. | -756 Thousand USD | 1158.995% |
| Jaguar Health, Inc. | 7.72 Million USD | -3.651% |
| Keros Therapeutics, Inc. | -664 Thousand USD | 1305.723% |
| Ligand Pharmaceuticals Incorporated | 119.75 Million USD | 93.315% |
| ContextLogic Inc. | 59 Million USD | 86.431% |
| MiMedx Group, Inc. | 266.84 Million USD | 97.0% |
| MEI Pharma, Inc. | 49.32 Million USD | 83.77% |
| NextCure, Inc. | -3.68 Million USD | 317.318% |
| Onconetix, Inc. | -1.12 Million USD | 810.278% |
| Oncternal Therapeutics, Inc. | -28.96 Million USD | 127.637% |
| Opthea Limited | 21.72 Thousand USD | -36760.037% |
| Psyence Biomedical Ltd. | -240.00 USD | 3335933.333% |
| Vaxcyte, Inc. | -75 Million USD | 110.675% |
| PDS Biotechnology Corporation | -57.32 Thousand USD | 14065.74% |
| Precigen, Inc. | 106 Thousand USD | -7452.83% |
| Pharming Group N.V. | 220.1 Million USD | 96.363% |
| Phathom Pharmaceuticals, Inc. | 515 Thousand USD | -1454.563% |
| Pieris Pharmaceuticals, Inc. | 1 Million USD | -693.459% |
| PureTech Health plc | -1.6 Million USD | 599.439% |
| Rigel Pharmaceuticals, Inc. | 109.77 Million USD | 92.707% |
| Avidity Biosciences, Inc. | -181.4 Million USD | 104.413% |
| Reviva Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Sangamo Therapeutics, Inc. | -45.32 Million USD | 117.664% |
| Sol-Gel Technologies Ltd. | -21.98 Million USD | 136.412% |
| Acelyrin, Inc. | -115 Thousand USD | 7061.739% |
| Salarius Pharmaceuticals, Inc. | -10.05 Thousand USD | 79753.766% |
| Summit Therapeutics Inc. | -2.05 Million USD | 490.537% |
| Sensei Biotherapeutics, Inc. | -571 Thousand USD | 1502.102% |
| Senti Biosciences, Inc. | -2.68 Million USD | 398.397% |
| Stoke Therapeutics, Inc. | 4.05 Million USD | -97.63% |
| Elevation Oncology, Inc. | -39 Thousand USD | 20628.205% |
| Alaunos Therapeutics, Inc. | -4.79 Million USD | 266.861% |
| Telomir Pharmaceuticals, Inc. Common Stock | -3.94 Million USD | 303.092% |
| Entrada Therapeutics, Inc. | 29.12 Million USD | 72.515% |
| VistaGen Therapeutics, Inc. | 496 Thousand USD | -1514.113% |
| Kintara Therapeutics, Inc. | -55 Thousand USD | 14656.364% |
| Wave Life Sciences Ltd. | 104.09 Million USD | 92.309% |
| Seer, Inc. | 7.02 Million USD | -13.932% |
| Verrica Pharmaceuticals Inc. | 4.37 Million USD | -82.869% |
| Aadi Bioscience, Inc. | 21.54 Million USD | 62.841% |
| ESSA Pharma Inc. | -118.49 Thousand USD | 6856.631% |
| GlycoMimetics, Inc. | -143.3 Thousand USD | 5686.842% |
| GT Biopharma, Inc. | - USD | -Infinity% |
| Inhibrx Biosciences, Inc. | 609 Thousand USD | -1214.614% |
| Akebia Therapeutics, Inc. | 120.47 Million USD | 93.355% |
| Catalyst Pharmaceuticals, Inc. | 313.67 Million USD | 97.448% |
| Longboard Pharmaceuticals, Inc. | -5000.00 USD | 160220.0% |
| Orchestra BioMed Holdings, Inc. | 2.57 Million USD | -211.033% |
| Alzamend Neuro, Inc. | -50.74 Thousand USD | 15878.479% |
| Sorrento Therapeutics, Inc. | 29.38 Million USD | 72.757% |
| TRACON Pharmaceuticals, Inc. | -232 Thousand USD | 3550.862% |
| Viracta Therapeutics, Inc. | -492 Thousand USD | 1727.236% |
| Rocket Pharmaceuticals, Inc. | -7.09 Million USD | 212.792% |
| Aptose Biosciences Inc. | -474.54 Thousand USD | 1787.09% |
| ZyVersa Therapeutics, Inc. | -10.4 Thousand USD | 77080.769% |
| Soligenix, Inc. | 97.31 Thousand USD | -8127.23% |
| Century Therapeutics, Inc. | -10.8 Million USD | 174.068% |
| Kura Oncology, Inc. | -849 Thousand USD | 1042.992% |
| TScan Therapeutics, Inc. | -67.1 Million USD | 111.931% |
| Intensity Therapeutics, Inc. | -147 Thousand USD | 5546.259% |
| Ocean Biomedical, Inc. | - USD | -Infinity% |
| CytomX Therapeutics, Inc. | 99.03 Million USD | 91.916% |
| Autolus Therapeutics plc | -4.86 Million USD | 264.496% |
| Mineralys Therapeutics, Inc. | - USD | -Infinity% |
| EyePoint Pharmaceuticals, Inc. | 41.38 Million USD | 80.655% |
| Eterna Therapeutics Inc. | -168 Thousand USD | 4865.476% |
| Adaptive Biotechnologies Corporation | 94.72 Million USD | 91.548% |
| GRI Bio, Inc. | 10.84 Million USD | 26.151% |
| Xenetic Biosciences, Inc. | 2.53 Million USD | -215.199% |
| Tenaya Therapeutics, Inc. | -8.68 Million USD | 192.161% |
| IGM Biosciences, Inc. | -211.66 Million USD | 103.782% |
| INmune Bio, Inc. | 155 Thousand USD | -5065.161% |
| Heron Therapeutics, Inc. | 61.93 Million USD | 87.074% |
| SAB Biotherapeutics, Inc. | -1.5 Million USD | 631.504% |
| Pasithea Therapeutics Corp. | -648.45 Thousand USD | 1334.629% |
| Entero Therapeutics, Inc. | -29.27 Thousand USD | 27448.5% |
| Milestone Pharmaceuticals Inc. | 402 Thousand USD | -1891.542% |
| X4 Pharmaceuticals, Inc. | -1.99 Million USD | 501.102% |
| Atara Biotherapeutics, Inc. | -313 Thousand USD | 2657.827% |
| Coherus BioSciences, Inc. | 94.46 Million USD | 91.525% |
| Verastem, Inc. | -62 Thousand USD | 13012.903% |
| Abeona Therapeutics Inc. | 2.43 Million USD | -228.789% |
| Pliant Therapeutics, Inc. | -261 Thousand USD | 3167.433% |
| Tonix Pharmaceuticals Holding Corp. | 3.02 Million USD | -164.486% |
| Histogen Inc. | 3.76 Million USD | -112.417% |
| Aprea Therapeutics, Inc. | 576.17 Thousand USD | -1289.499% |
| Surrozen, Inc. | -27.23 Million USD | 129.401% |
| Organovo Holdings, Inc. | -5.38 Million USD | 248.562% |
| Lixte Biotechnology Holdings, Inc. | - USD | -Infinity% |
| Ovid Therapeutics Inc. | -1.2 Million USD | 764.465% |
| Panbela Therapeutics, Inc. | -25.64 Million USD | 131.216% |
| CASI Pharmaceuticals, Inc. | 20.05 Million USD | 60.074% |
| Cadrenal Therapeutics, Inc. Common Stock | -1980.00 USD | 404443.434% |
| Centessa Pharmaceuticals plc | 6.06 Million USD | -31.972% |
| Hepion Pharmaceuticals, Inc. | -67.13 Thousand USD | 12025.936% |
| Arcturus Therapeutics Holdings Inc. | 154.79 Million USD | 94.828% |
| BioRestorative Therapies, Inc. | 145.8 Thousand USD | -5391.084% |
| Apollomics, Inc. | 127 Thousand USD | -6203.937% |
| Amarin Corporation plc | 165.54 Million USD | 95.164% |
| Mesoblast Limited | -9.81 Million USD | 181.569% |
| Turnstone Biologics Corp. | 16.5 Million USD | 51.496% |
| Kymera Therapeutics, Inc. | -110.48 Million USD | 107.246% |
| Synaptogenix, Inc. | -6347.00 USD | 126238.333% |
| Tiziana Life Sciences Ltd | -51 Thousand USD | 15798.039% |
| Aurinia Pharmaceuticals Inc. | 161.36 Million USD | 95.039% |
| BriaCell Therapeutics Corp. | - USD | -Infinity% |
| Monopar Therapeutics Inc. | - USD | -Infinity% |
| Exelixis, Inc. | 1.75 Billion USD | 99.545% |
| Better Therapeutics, Inc. | -2.72 Million USD | 393.368% |
| Nurix Therapeutics, Inc. | -112.16 Million USD | 107.138% |
| Apellis Pharmaceuticals, Inc. | 338.08 Million USD | 97.632% |
| NLS Pharmaceutics AG | -11.4 Thousand USD | 70278.822% |
| Dermata Therapeutics, Inc. | - USD | -Infinity% |
| Aridis Pharmaceuticals, Inc. | - USD | -Infinity% |
| Gritstone bio, Inc. | -6.26 Million USD | 227.891% |
| Jasper Therapeutics, Inc. | -1.1 Million USD | 822.563% |
| TNF Pharmaceuticals, Inc. | - USD | -Infinity% |
| Avid Bioservices, Inc. | 7.31 Million USD | -9.401% |
| Insmed Incorporated | 239.63 Million USD | 96.659% |
| Virpax Pharmaceuticals, Inc. | - USD | -Infinity% |
| MediWound Ltd. | 3.57 Million USD | -123.756% |
| OmniAb, Inc. | 14.66 Million USD | 45.415% |
| Alector, Inc. | -95.05 Million USD | 108.423% |
| Seres Therapeutics, Inc. | 125.62 Million USD | 93.627% |
| Checkpoint Therapeutics, Inc. | -43.46 Million USD | 118.42% |
| Zai Lab Limited | 170.9 Million USD | 95.315% |
| Revance Therapeutics, Inc. | 81.87 Million USD | 90.222% |
| Aura Biosciences, Inc. | -1.29 Million USD | 718.224% |
| Lyell Immunopharma, Inc. | 130 Thousand USD | -6058.462% |
| Immunic, Inc. | -111 Thousand USD | 7312.613% |
| Tarsus Pharmaceuticals, Inc. | 15.85 Million USD | 49.502% |
| Veracyte, Inc. | 248.14 Million USD | 96.774% |
| InMed Pharmaceuticals Inc. | -6.98 Billion USD | 100.115% |
| FibroGen, Inc. | 128.9 Million USD | 93.789% |
| SeaStar Medical Holding Corporation | - USD | -Infinity% |
| Adial Pharmaceuticals, Inc. | -564.00 USD | 1419603.546% |
| Sonnet BioTherapeutics Holdings, Inc. | -11.66 Million USD | 168.622% |
| Jazz Pharmaceuticals plc | 3.39 Billion USD | 99.764% |
| Cyclacel Pharmaceuticals, Inc. | 389 Thousand USD | -1958.098% |
| Amylyx Pharmaceuticals, Inc. | 355.34 Million USD | 97.747% |
| TG Therapeutics, Inc. | 219.1 Million USD | 96.346% |
| Galecto, Inc. | -830 Thousand USD | 1064.578% |
| Calithera Biosciences, Inc. | -1.38 Million USD | 678.051% |
| Fortrea Holdings Inc. | 424 Million USD | 98.112% |
| KalVista Pharmaceuticals, Inc. | -86.16 Million USD | 109.291% |
| Aptevo Therapeutics Inc. | -567 Thousand USD | 1511.993% |
| XBiotech Inc. | -1.74 Million USD | 559.06% |
| Jasper Therapeutics, Inc. | -1.1 Million USD | 822.563% |
| Lyra Therapeutics, Inc. | -46.47 Million USD | 117.228% |
| Foghorn Therapeutics Inc. | -75.53 Million USD | 110.599% |
| Y-mAbs Therapeutics, Inc. | 73.4 Million USD | 89.093% |
| Theravance Biopharma, Inc. | 16.8 Million USD | 52.354% |
| Ultragenyx Pharmaceutical Inc. | 389.04 Million USD | 97.942% |
| Metagenomi, Inc. Common Stock | -49.64 Million USD | 116.126% |
| Vaxxinity, Inc. | -2.23 Million USD | 458.371% |
| BioCryst Pharmaceuticals, Inc. | 326.75 Million USD | 97.55% |
| Gain Therapeutics, Inc. | -11.32 Million USD | 170.7% |
| Cartesian Therapeutics, Inc. | 24.45 Million USD | 67.257% |
| NexImmune, Inc. | -1.02 Million USD | 881.095% |
| Creative Medical Technology Holdings, Inc. | 5400.00 USD | -148159.259% |
| Marker Therapeutics, Inc. | -7.1 Million USD | 212.671% |
| Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 99.929% |
| Chemomab Therapeutics Ltd. | -66.82 Thousand USD | 12080.188% |
| Scopus BioPharma Inc. | - USD | -Infinity% |
| RAPT Therapeutics, Inc. | -3.55 Million USD | 325.458% |
| Ainos, Inc. | -253.73 Thousand USD | 3255.285% |
| Pluri Inc. | 322 Thousand USD | -2386.335% |
| Prothena Corporation plc | -129.2 Million USD | 106.197% |
| Adaptimmune Therapeutics plc | 50.42 Million USD | 84.123% |
| Celularity Inc. | 6.75 Million USD | -18.52% |
| Rallybio Corporation | -150 Thousand USD | 5437.333% |
| Cue Biopharma, Inc. | -32.6 Million USD | 124.553% |
| MeiraGTx Holdings plc | 287 Thousand USD | -2689.547% |
| Omeros Corporation | -69.77 Million USD | 111.473% |
| Humacyte, Inc. | -76.55 Million USD | 110.459% |
| Immunocore Holdings plc | 248.39 Million USD | 96.777% |
| Cocrystal Pharma, Inc. | -15.16 Million USD | 152.779% |
| Cidara Therapeutics, Inc. | 62.38 Million USD | 87.166% |
| Blueprint Medicines Corporation | 236.58 Million USD | 96.616% |
| CalciMedica, Inc. | -58 Thousand USD | 13903.448% |
| Cabaletta Bio, Inc. | -1.42 Million USD | 661.431% |
| Marinus Pharmaceuticals, Inc. | 29.05 Million USD | 72.445% |
| Scholar Rock Holding Corporation | -2.84 Million USD | 381.505% |
| Sana Biotechnology, Inc. | -30.86 Million USD | 125.939% |
| Pulmatrix, Inc. | -8.22 Million USD | 197.397% |
| Elicio Therapeutics, Inc. | -1.17 Million USD | 784.274% |
| Vigil Neuroscience, Inc. | -399 Thousand USD | 2106.516% |
| Intellia Therapeutics, Inc. | -398.79 Million USD | 102.008% |
| Adlai Nortye Ltd. American Depositary Shares | 2.77 Million USD | -188.444% |
| Cytokinetics, Incorporated | -322.59 Million USD | 102.482% |
| Eloxx Pharmaceuticals, Inc. | - USD | -Infinity% |
| Nutriband Inc. | 862.1 Thousand USD | -828.657% |
| Protara Therapeutics, Inc. | -341 Thousand USD | 2447.801% |
| Vor Biopharma Inc. | -3.49 Million USD | 329.267% |
| Roivant Sciences Ltd. | 109.23 Million USD | 92.671% |
| Evogene Ltd. | 1.39 Million USD | -472.266% |
| ProKidney Corp. | -3.16 Million USD | 352.635% |
| Applied Therapeutics, Inc. | -43.91 Million USD | 118.232% |
| Hoth Therapeutics, Inc. | - USD | -Infinity% |
| BridgeBio Pharma, Inc. | 6.85 Million USD | -16.757% |
| CorMedix Inc. | -205.56 Thousand USD | 3994.689% |
| BioLineRx Ltd. | 1.1 Million USD | -622.563% |
| Tango Therapeutics, Inc. | -78.67 Million USD | 110.177% |
| Galectin Therapeutics Inc. | -33 Thousand USD | 24360.606% |
| Atai Life Sciences N.V. | -5000.00 USD | 160220.0% |
| Renovaro Biosciences Inc. | -121.85 Thousand USD | 6669.888% |
| Aerovate Therapeutics, Inc. | -96 Thousand USD | 8439.583% |
| Zentalis Pharmaceuticals, Inc. | -1.38 Million USD | 676.386% |
| Sagimet Biosciences Inc. | 2 Million USD | -300.3% |
| MediciNova, Inc. | 979.7 Thousand USD | -717.185% |
| Praxis Precision Medicines, Inc. | -84.31 Million USD | 109.495% |
| Cardio Diagnostics Holdings, Inc. | -94.55 Thousand USD | 8567.03% |
| GeoVax Labs, Inc. | -20.72 Million USD | 138.638% |
| Axsome Therapeutics, Inc. | 244.53 Million USD | 96.726% |
| Biomea Fusion, Inc. | -4.2 Million USD | 290.574% |
| PTC Therapeutics, Inc. | 872.33 Million USD | 99.082% |
| Mereo BioPharma Group plc | 7.42 Million USD | -7.81% |
| Cullinan Oncology, Inc. | -310 Thousand USD | 2682.581% |
| Syndax Pharmaceuticals, Inc. | -12 Thousand USD | 66816.667% |
| Absci Corporation | -41.84 Million USD | 119.131% |
| NRx Pharmaceuticals, Inc. | -5000.00 USD | 160220.0% |
| 4D Molecular Therapeutics, Inc. | -76.37 Million USD | 110.483% |
| Dyne Therapeutics, Inc. | -2.46 Million USD | 425.315% |
| Kiniksa Pharmaceuticals, Ltd. | 213.73 Million USD | 96.254% |
| Ventyx Biosciences, Inc. | -941 Thousand USD | 950.797% |
| Allakos Inc. | -6.14 Million USD | 230.37% |
| Imunon, Inc. | -720 Thousand USD | 1211.937% |
| Fulcrum Therapeutics, Inc. | -68.99 Million USD | 111.604% |
| Corcept Therapeutics Incorporated | 475.89 Million USD | 98.318% |
| BioAtla, Inc. | -103.73 Million USD | 107.718% |
| NLS Pharmaceutics AG | -11.4 Thousand USD | 70278.822% |
| Bio-Path Holdings, Inc. | -178 Thousand USD | 4597.753% |
| Allogene Therapeutics, Inc. | -242.81 Million USD | 103.297% |
| Larimar Therapeutics, Inc. | -311 Thousand USD | 2674.277% |
| XOMA Corporation | 3.86 Million USD | -107.356% |
| Kezar Life Sciences, Inc. | -70.08 Million USD | 111.423% |
| Cara Therapeutics, Inc. | 14.79 Million USD | 45.883% |
| aTyr Pharma, Inc. | -2.38 Million USD | 435.26% |
| Aligos Therapeutics, Inc. | 12.46 Million USD | 35.746% |
| Akero Therapeutics, Inc. | -29 Thousand USD | 27706.897% |
| Viridian Therapeutics, Inc. | -1 Million USD | 894.246% |
| Eliem Therapeutics, Inc. | - USD | -Infinity% |
| EyeGate Pharmaceuticals, Inc. | 13.00 USD | -61584515.385% |
| Akari Therapeutics, Plc | -4000.00 USD | 200250.0% |
| Tevogen Bio Holdings Inc. | - USD | -Infinity% |
| Halozyme Therapeutics, Inc. | 636.89 Million USD | 98.743% |
| Lexaria Bioscience Corp. | 194.7 Thousand USD | -4011.798% |
| UroGen Pharma Ltd. | 73.35 Million USD | 89.086% |
| Sutro Biopharma, Inc. | -26.69 Million USD | 129.992% |
| ZIVO Bioscience, Inc. | 11.61 Thousand USD | -68857.795% |
| Orgenesis Inc. | -5.72 Million USD | 239.843% |
| Entera Bio Ltd. | -56 Thousand USD | 14396.429% |
| GH Research PLC | -315 Thousand USD | 2641.587% |
| Lisata Therapeutics, Inc. | -189 Thousand USD | 4335.979% |
| Reneo Pharmaceuticals, Inc. | -525 Thousand USD | 1624.952% |
| Xencor, Inc. | -85.26 Million USD | 109.39% |
| 60 Degrees Pharmaceuticals, Inc. | -220.97 Thousand USD | 3723.001% |
| Replimune Group, Inc. | -2.65 Million USD | 401.544% |
| Coeptis Therapeutics Holdings, Inc. | -1 Million USD | 899.612% |
| Vanda Pharmaceuticals Inc. | 177.84 Million USD | 95.498% |
| Lexaria Bioscience Corp. | 194.7 Thousand USD | -4011.798% |
| Portage Biotech Inc. | -54 Thousand USD | 14925.926% |
| Cardio Diagnostics Holdings, Inc. | -94.55 Thousand USD | 8567.03% |
| Olema Pharmaceuticals, Inc. | -377 Thousand USD | 2223.607% |
| OncoCyte Corporation | 413 Thousand USD | -1838.499% |
| Qualigen Therapeutics, Inc. | -4495.00 USD | 178209.01% |
| Processa Pharmaceuticals, Inc. | -222.00 USD | 3606406.306% |
| Purple Biotech Ltd. | -196 Thousand USD | 4184.694% |
| CollPlant Biotechnologies Ltd. | 8.96 Million USD | 10.727% |
| scPharmaceuticals Inc. | 9.78 Million USD | 18.156% |
| ProMIS Neurosciences, Inc. | -10.44 Million USD | 176.649% |
| HilleVax, Inc. | -2.15 Million USD | 471.336% |
| NeuroSense Therapeutics Ltd. | -97 Thousand USD | 8353.608% |
| Tharimmune, Inc. | - USD | -Infinity% |
| Genprex, Inc. | -15 Thousand USD | 53459.104% |
| Neumora Therapeutics, Inc. Common Stock | -668 Thousand USD | 1298.503% |
| Atossa Therapeutics, Inc. | -23 Thousand USD | 34908.696% |
| XTL Biopharmaceuticals Ltd. | - USD | -Infinity% |
| Virios Therapeutics, Inc. | - USD | -Infinity% |
| OKYO Pharma Limited | -7506.16 USD | 106759.064% |
| Savara Inc. | -44.26 Million USD | 118.088% |
| Curis, Inc. | 9.81 Million USD | 18.398% |
| Daré Bioscience, Inc. | 2.76 Million USD | -189.075% |
| Carmell Therapeutics Corporation | -124.78 Thousand USD | 6515.681% |
| Titan Pharmaceuticals, Inc. | -1.72 Million USD | 563.042% |
| Achieve Life Sciences, Inc. | -228 Thousand USD | 3611.404% |
| BeiGene, Ltd. | 2.07 Billion USD | 99.615% |
| Kiromic BioPharma, Inc. | -2.79 Million USD | 386.348% |
| Revolution Medicines, Inc. Warrant | -399.66 Million USD | 102.003% |
| Protagonist Therapeutics, Inc. | 56.68 Million USD | 85.877% |
| Erasca, Inc. | -3.73 Million USD | 314.523% |
| bluebird bio, Inc. | -4.03 Million USD | 298.66% |
| Protagenic Therapeutics, Inc. | -28.21 Thousand USD | 28471.961% |
| BioMarin Pharmaceutical Inc. | 1.9 Billion USD | 99.58% |
| DBV Technologies S.A. | 15.72 Million USD | 49.097% |
| Protagenic Therapeutics, Inc. | -28.21 Thousand USD | 28471.961% |
| Moderna, Inc. | 2.15 Billion USD | 99.628% |
| Vincerx Pharma, Inc. | -915 Thousand USD | 974.973% |
| Molecular Templates, Inc. | 50.39 Million USD | 84.114% |
| Acrivon Therapeutics, Inc. Common Stock | -536 Thousand USD | 1593.657% |
| Travere Therapeutics, Inc. | 133.78 Million USD | 94.016% |
| Monte Rosa Therapeutics, Inc. | -6.22 Million USD | 228.672% |
| Spruce Biosciences, Inc. | -39.34 Million USD | 120.349% |
| Celldex Therapeutics, Inc. | -111.12 Million USD | 107.204% |
| Cogent Biosciences, Inc. | -3.58 Million USD | 323.133% |
| MacroGenics, Inc. | 50.52 Million USD | 84.155% |
| RenovoRx, Inc. | - USD | -Infinity% |
| Adicet Bio, Inc. | -6.09 Million USD | 231.289% |
| Prime Medicine, Inc. | -147.9 Million USD | 105.413% |
| Aditxt, Inc. | -111.66 Thousand USD | 7269.98% |
| Adagene Inc. | 18.11 Million USD | 55.796% |
| Estrella Immunopharma, Inc. | - USD | -Infinity% |
| Quantum-Si incorporated | 488 Thousand USD | -1540.574% |
| Maravai LifeSciences Holdings, Inc. | 140.2 Million USD | 94.29% |
| Acurx Pharmaceuticals, Inc. | - USD | -Infinity% |
| Voyager Therapeutics, Inc. | 157.83 Million USD | 94.928% |
| SciSparc Ltd. | 2.19 Million USD | -264.572% |
| Vericel Corporation | 135.57 Million USD | 94.095% |
| Revelation Biosciences, Inc. | -25.04 Thousand USD | 32061.356% |
| Minerva Neurosciences, Inc. | -30.98 Thousand USD | 25940.811% |
| Generation Bio Co. | -73.91 Million USD | 110.832% |
| Astria Therapeutics, Inc. | - USD | -Infinity% |
| Black Diamond Therapeutics, Inc. | -437 Thousand USD | 1932.037% |
| Arcutis Biotherapeutics, Inc. | 54.61 Million USD | 85.342% |
| Invivyd, Inc. | -2.02 Million USD | 494.773% |
| Relay Therapeutics, Inc. | -300.84 Million USD | 102.661% |
| Quoin Pharmaceuticals, Ltd. | -103.43 Thousand USD | 7839.902% |
| Spero Therapeutics, Inc. | 96.36 Million USD | 91.692% |
| Artelo Biosciences, Inc. | - USD | -Infinity% |
| 2seventy bio, Inc. | 98.28 Million USD | 91.855% |
| ADMA Biologics, Inc. | 88.21 Million USD | 90.925% |
| Clene Inc. | 533 Thousand USD | -1402.064% |
| Capricor Therapeutics, Inc. | 24.1 Million USD | 66.793% |
| Boundless Bio, Inc. Common Stock | -957 Thousand USD | 936.573% |
| GeoVax Labs, Inc. | -20.72 Million USD | 138.638% |
| Recursion Pharmaceuticals, Inc. | 1.98 Million USD | -302.716% |
| Citius Pharmaceuticals, Inc. | -194.31 Thousand USD | 4220.093% |
| Contineum Therapeutics, Inc. Class A Common Stock | 49.8 Million USD | 83.925% |
| Relmada Therapeutics, Inc. | - USD | -Infinity% |
| Finch Therapeutics Group, Inc. | -7.09 Million USD | 212.888% |
| ALX Oncology Holdings Inc. | -836 Thousand USD | 1057.656% |
| Vir Biotechnology, Inc. | 83.41 Million USD | 90.402% |
| Evaxion Biotech A/S | 73.11 Thousand USD | -10850.323% |
| Ocular Therapeutix, Inc. | 53.16 Million USD | 84.94% |
| Verve Therapeutics, Inc. | -173.18 Million USD | 104.623% |
| Trevena, Inc. | 1.45 Million USD | -450.241% |
| Surrozen, Inc. | -27.23 Million USD | 129.401% |
| Tyra Biosciences, Inc. | -353 Thousand USD | 2367.989% |
| Cingulate Inc. | -582.91 Thousand USD | 1473.435% |
| Galmed Pharmaceuticals Ltd. | -31 Thousand USD | 25925.806% |
| Unity Biotechnology, Inc. | -19.69 Million USD | 140.642% |
| Tenax Therapeutics, Inc. | -7570.00 USD | 105859.577% |
| Terns Pharmaceuticals, Inc. | -881 Thousand USD | 1008.74% |
| ACADIA Pharmaceuticals Inc. | 680.7 Million USD | 98.824% |
| Connect Biopharma Holdings Limited | -988 Thousand USD | 910.324% |
| Clearmind Medicine Inc. | -56.34 Thousand USD | 14309.648% |
| Kronos Bio, Inc. | 1.37 Million USD | -483.528% |
| Bolt Biotherapeutics, Inc. | -53.66 Million USD | 114.918% |
| CERo Therapeutics Holdings, Inc. | - USD | -Infinity% |
| Viking Therapeutics, Inc. | -292 Thousand USD | 2841.781% |
| Statera Biopharma, Inc. | -488.31 Thousand USD | 1739.519% |
| ImmunityBio, Inc. | -17.89 Million USD | 144.751% |
| Korro Bio, Inc. | -3.63 Million USD | 320.551% |
| Kineta, Inc. | 5.43 Million USD | -47.359% |
| BioVie Inc. | -229.37 Thousand USD | 3590.324% |
| Codexis, Inc. | 57.33 Million USD | 86.036% |
| Celularity Inc. | 6.75 Million USD | -18.52% |
| Crinetics Pharmaceuticals, Inc. | 4.01 Million USD | -99.502% |
| Celcuity Inc. | -142.77 Thousand USD | 5707.542% |
| Virax Biolabs Group Limited | 50.59 Thousand USD | -15725.262% |
| Cibus, Inc. | 1.42 Million USD | -463.01% |
| Eledon Pharmaceuticals, Inc. | -374 Thousand USD | 2240.642% |
| eFFECTOR Therapeutics, Inc. | -22.91 Million USD | 134.932% |
| IN8bio, Inc. | -2.5 Million USD | 420.112% |
| Kodiak Sciences Inc. | -25.94 Million USD | 130.855% |
| Annexon, Inc. | -3.26 Million USD | 345.057% |
| Adverum Biotechnologies, Inc. | -2.04 Million USD | 491.683% |
| Assembly Biosciences, Inc. | -41.73 Million USD | 119.182% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | -1150.938% |
| Ionis Pharmaceuticals, Inc. | 778.51 Million USD | 98.972% |
| Eyenovia, Inc. | - USD | -Infinity% |
| Puma Biotechnology, Inc. | 172.95 Million USD | 95.371% |
| Conduit Pharmaceuticals Inc. | - USD | -Infinity% |
| Xilio Therapeutics, Inc. | -1.9 Million USD | 521.368% |
| Arcellx, Inc. | 108.27 Million USD | 92.606% |
| Cardiff Oncology, Inc. | -32.36 Million USD | 124.734% |
| Enanta Pharmaceuticals, Inc. | 79.2 Million USD | 89.892% |
| Regulus Therapeutics Inc. | -21.15 Million USD | 137.85% |
| Moolec Science SA | -143.3 Thousand USD | 5686.686% |
| Acumen Pharmaceuticals, Inc. | -42.31 Million USD | 118.919% |
| Geron Corporation | -123.5 Million USD | 106.482% |
| LAVA Therapeutics N.V. | 3.28 Million USD | -143.566% |
| Royalty Pharma plc | 1.79 Billion USD | 99.554% |
| Atea Pharmaceuticals, Inc. | -70.09 Million USD | 111.422% |
| Greenwich LifeSciences, Inc. | -3612.00 USD | 221750.055% |
| TFF Pharmaceuticals, Inc. | 231.39 Thousand USD | -3359.944% |
| Mersana Therapeutics, Inc. | -111.41 Million USD | 107.186% |
| Humacyte, Inc. | -76.55 Million USD | 110.459% |
| Structure Therapeutics Inc. | -949.17 Thousand USD | 943.47% |
| 89bio, Inc. | -273 Thousand USD | 3032.601% |
| PMV Pharmaceuticals, Inc. | -1.25 Million USD | 736.913% |
| Avenue Therapeutics, Inc. | - USD | -Infinity% |
| Genelux Corporation | -848 Thousand USD | 1044.104% |
| Trevi Therapeutics, Inc. | -123 Thousand USD | 6608.943% |
| Lexicon Pharmaceuticals, Inc. | 1.11 Million USD | -615.46% |
| Notable Labs, Ltd. | 113 Thousand USD | -6984.956% |
| Liquidia Corporation | 14.6 Million USD | 45.164% |
| Mustang Bio, Inc. | -2.22 Million USD | 459.82% |
| Immunovant, Inc. | -231 Thousand USD | 3565.801% |
| Quantum-Si incorporated | 488 Thousand USD | -1540.574% |
| Arbutus Biopharma Corporation | -55.55 Million USD | 114.41% |
| DiaMedica Therapeutics Inc. | -30 Thousand USD | 26786.667% |
| Vera Therapeutics, Inc. | 1.86 Million USD | -329.968% |
| Acasti Pharma Inc. | -11 Thousand USD | 72881.818% |
| MiNK Therapeutics, Inc. | -204.61 Thousand USD | 4012.676% |
| Pasithea Therapeutics Corp. | -648.45 Thousand USD | 1334.629% |
| Xenon Pharmaceuticals Inc. | -167.51 Million USD | 104.779% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | -605.636% |
| NeuroBo Pharmaceuticals, Inc. | - USD | -Infinity% |
| Tempest Therapeutics, Inc. | -381 Thousand USD | 2201.312% |
| Soleno Therapeutics, Inc. | -1.95 Million USD | 508.887% |
| PepGen Inc. | -1.18 Million USD | 776.182% |
| Moleculin Biotech, Inc. | -127 Thousand USD | 6403.937% |
| United Therapeutics Corporation | 2.07 Billion USD | 99.613% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | 134.965% |
| Solid Biosciences Inc. | -76.56 Million USD | 110.457% |
| BriaCell Therapeutics Corp. | -82.58 Thousand USD | 9794.489% |
| Immuneering Corporation | -764.13 Thousand USD | 1147.717% |
| Lixte Biotechnology Holdings, Inc. | - USD | -Infinity% |
| Silo Pharma, Inc. | 66.26 Thousand USD | -11981.975% |
| Belite Bio, Inc | -399 Thousand USD | 2106.516% |
| XOMA Corporation | 3.86 Million USD | -107.356% |
| ARS Pharmaceuticals, Inc. | -20.03 Million USD | 139.958% |
| Bionomics Limited | -434.44 Thousand USD | 1942.794% |
| Apogee Therapeutics, Inc. | - USD | -Infinity% |
| Alpha Tau Medical Ltd. | -1.07 Million USD | 845.438% |
| uniQure N.V. | 2.21 Million USD | -261.445% |
| Cassava Sciences, Inc. | -89.42 Million USD | 108.953% |
| Estrella Immunopharma, Inc. | - USD | -Infinity% |
| Poseida Therapeutics, Inc. | -92.06 Million USD | 108.696% |
| Forte Biosciences, Inc. | -9000.00 USD | 89055.556% |
| Anebulo Pharmaceuticals, Inc. | - USD | -Infinity% |
| Enlivex Therapeutics Ltd. | -835 Thousand USD | 1058.802% |
| Conduit Pharmaceuticals Inc. | - USD | -Infinity% |
| SeaStar Medical Holding Corporation | - USD | -Infinity% |
| FibroBiologics, Inc. Common Stock | -437 Thousand USD | 1932.037% |
| Altimmune, Inc. | -65.37 Million USD | 112.247% |
| Amicus Therapeutics, Inc. | 362.03 Million USD | 97.789% |
| Alpha Tau Medical Ltd. | -1.07 Million USD | 845.438% |
| Compugen Ltd. | 31.45 Million USD | 74.548% |
| Peak Bio, Inc. | 367.76 Thousand USD | -2076.91% |
| Zevra Therapeutics, Inc. | 24.51 Million USD | 67.344% |
| Benitec Biopharma Inc. | 108 Thousand USD | -7312.963% |
| Spyre Therapeutics, Inc. | -78 Thousand USD | 10364.103% |
| NKGen Biotech, Inc. Common Stock | -1.2 Million USD | 765.503% |
| Zura Bio Limited | - USD | -Infinity% |
| PolyPid Ltd. | -1.82 Million USD | 539.407% |
| Aileron Therapeutics, Inc. | -119 Thousand USD | 6827.731% |
| NKGen Biotech, Inc. Warrants | -1.2 Million USD | 765.503% |
| Instil Bio, Inc. | -4.75 Million USD | 268.335% |
| argenx SE | 1.1 Billion USD | 99.278% |
| Immunome, Inc. | -8.9 Million USD | 189.884% |
| Compass Therapeutics, Inc. | -1.89 Million USD | 523.598% |
| Verona Pharma plc | -679.62 Thousand USD | 1278.004% |
| enGene Holdings Inc. Warrants | -175 Thousand USD | 4674.857% |
| Shattuck Labs, Inc. | -2.38 Million USD | 435.681% |
| CervoMed Inc. | -1.29 Million USD | 718.88% |
| LENZ Therapeutics, Inc. | -2.4 Million USD | 432.613% |
| Plus Therapeutics, Inc. | -4.77 Million USD | 267.595% |
| Dianthus Therapeutics, Inc. | 2.47 Million USD | -223.998% |
| Moolec Science SA | -143.3 Thousand USD | 5686.686% |
| Enveric Biosciences, Inc. | -408.03 Thousand USD | 2062.111% |
| Inovio Pharmaceuticals, Inc. | -2.67 Million USD | 399.679% |
| AnaptysBio, Inc. | 14.78 Million USD | 45.836% |
| Design Therapeutics, Inc. | -537 Thousand USD | 1590.875% |
| Leap Therapeutics, Inc. | -427 Thousand USD | 1974.941% |
| NeurAxis, Inc. | 2.15 Million USD | -271.215% |
| Seelos Therapeutics, Inc. | 2.14 Million USD | -273.066% |
| Lumos Pharma, Inc. | 2 Million USD | -298.904% |
| Achilles Therapeutics plc | -4.73 Million USD | 269.215% |
| enGene Holdings Inc. Common Stock | -175 Thousand USD | 4674.857% |
| 180 Life Sciences Corp. | -105.67 Thousand USD | 7676.059% |
| Opiant Pharmaceuticals, Inc. | 31.65 Million USD | 74.712% |
| CERo Therapeutics Holdings, Inc. | - USD | -Infinity% |
| Nutriband Inc. | 862.1 Thousand USD | -828.657% |
| ORIC Pharmaceuticals, Inc. | -1.03 Million USD | 875.775% |
| CG Oncology, Inc. Common stock | -45.54 Million USD | 117.577% |
| Fractyl Health, Inc. Common Stock | 43 Thousand USD | -18518.605% |
| Rani Therapeutics Holdings, Inc. | -822 Thousand USD | 1073.966% |
| MoonLake Immunotherapeutics | -13.15 Thousand USD | 60945.113% |
| Palisade Bio, Inc. | 246 Thousand USD | -3154.472% |
| Tourmaline Bio, Inc. | -33 Thousand USD | 24360.606% |
| Beam Therapeutics Inc. | -59.67 Million USD | 113.417% |
| Neurogene Inc. | -3.26 Million USD | 345.432% |
| Mirum Pharmaceuticals, Inc. | 139.33 Million USD | 94.254% |
| AEON Biopharma, Inc. | - USD | -Infinity% |
| CARGO Therapeutics, Inc. Common Stock | -3.69 Million USD | 316.847% |
| Sesen Bio, Inc. | 40 Million USD | 79.985% |
| Enliven Therapeutics, Inc. | -297 Thousand USD | 2795.623% |
| Kiora Pharmaceuticals, Inc. | -4.02 Million USD | 298.806% |
| Iovance Biotherapeutics, Inc. | -9.56 Million USD | 183.692% |
| Taysha Gene Therapies, Inc. | 14.08 Million USD | 43.139% |
| Athira Pharma, Inc. | -969 Thousand USD | 926.213% |
| Vaccinex, Inc. | -16 Million USD | 150.025% |
| HCW Biologics Inc. | -574.82 Thousand USD | 1492.774% |
| XOMA Corporation | 3.86 Million USD | -107.356% |
| Nektar Therapeutics | 53.47 Million USD | 85.029% |
| Arvinas, Inc. | 71.8 Million USD | 88.85% |
| Tevogen Bio Holdings Inc. | - USD | -Infinity% |
| Merus N.V. | -83.46 Million USD | 109.593% |
| Omega Therapeutics, Inc. | -62.77 Million USD | 112.753% |
| Quince Therapeutics, Inc. | -322 Thousand USD | 2586.335% |
| Rezolute, Inc. | -36 Thousand USD | 22338.889% |
| Clene Inc. | 533 Thousand USD | -1402.064% |
| Indaptus Therapeutics, Inc. | -1284.00 USD | 623620.249% |
| BeyondSpring Inc. | 1.75 Million USD | -357.224% |
| Synlogic, Inc. | -1.92 Million USD | 516.112% |
| Allarity Therapeutics, Inc. | -37 Thousand USD | 21737.838% |
| Phio Pharmaceuticals Corp. | -6.33 Million USD | 226.437% |
| Peak Bio, Inc. | 367.76 Thousand USD | -2076.91% |
| Werewolf Therapeutics, Inc. | -18.96 Million USD | 142.219% |
| Krystal Biotech, Inc. | 47.6 Million USD | 83.182% |
| Karyopharm Therapeutics Inc. | 141.09 Million USD | 94.326% |
| SpringWorks Therapeutics, Inc. | 5.02 Million USD | -59.323% |
| Lipella Pharmaceuticals Inc. | -2.58 Million USD | 409.205% |
| MannKind Corporation | 136.19 Million USD | 94.121% |
| Ikena Oncology, Inc. | -50.49 Million USD | 115.856% |
| Cyclerion Therapeutics, Inc. | - USD | -Infinity% |
| Gyre Therapeutics, Inc. | 108.81 Million USD | 92.642% |
| Gossamer Bio, Inc. | -4.38 Million USD | 282.577% |
| CohBar, Inc. | - USD | -Infinity% |
| Cognition Therapeutics, Inc. | -252 Thousand USD | 3276.984% |
| NRx Pharmaceuticals, Inc. | -5000.00 USD | 160220.0% |
| Legend Biotech Corporation | 140.92 Million USD | 94.319% |
| Mural Oncology plc | -2.56 Million USD | 411.882% |
| Biora Therapeutics, Inc. | -551 Thousand USD | 1552.995% |
| PaxMedica, Inc. Common Stock | - USD | -Infinity% |
| Disc Medicine, Inc. | -100 Thousand USD | 8106.0% |
| Champions Oncology, Inc. | 20.75 Million USD | 61.424% |
| REGENXBIO Inc. | 53.02 Million USD | 84.903% |
| Ensysce Biosciences, Inc. | -5.35 Million USD | 249.451% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Cellectar Biosciences, Inc. | -192.37 Thousand USD | 4261.663% |
| Edgewise Therapeutics, Inc. | -1.73 Million USD | 562.24% |
| Vaxart, Inc. | -60.76 Million USD | 113.176% |
| PharmaCyte Biotech, Inc. | - USD | -Infinity% |
| Aldeyra Therapeutics, Inc. | -262.78 Thousand USD | 3146.655% |
| Cellectis S.A. | 18 Thousand USD | -44377.778% |
| Longeveron Inc. | 221 Thousand USD | -3522.624% |
| Repare Therapeutics Inc. | -80.07 Million USD | 109.999% |
| Sarepta Therapeutics, Inc. | 1.09 Billion USD | 99.268% |
| Inozyme Pharma, Inc. | -1.29 Million USD | 718.702% |
| Revolution Medicines, Inc. | -399.66 Million USD | 102.003% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| Third Harmonic Bio, Inc. | -35 Thousand USD | 22974.286% |
| ArriVent BioPharma, Inc. Common Stock | - USD | -Infinity% |
| AN2 Therapeutics, Inc. | - USD | -Infinity% |
| Anixa Biosciences, Inc. | 49 Thousand USD | -16238.776% |
| Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | 99.907% |
| Denali Therapeutics Inc. | -93.34 Million USD | 108.577% |
| Revelation Biosciences, Inc. | -25.04 Thousand USD | 32061.356% |
| Veru Inc. | 7.56 Million USD | -5.816% |
| Corvus Pharmaceuticals, Inc. | -151 Thousand USD | 5401.987% |
| Cingulate Inc. | -582.91 Thousand USD | 1473.435% |
| Passage Bio, Inc. | -3.72 Million USD | 315.157% |
| Context Therapeutics Inc. | -12.04 Thousand USD | 66572.933% |
| Exicure, Inc. | -1.42 Million USD | 662.614% |
| Day One Biopharmaceuticals, Inc. | -383 Thousand USD | 2190.339% |
| Oramed Pharmaceuticals Inc. | 2.7 Million USD | -196.189% |
| Scinai Immunotherapeutics Ltd. | -512.67 Thousand USD | 1661.613% |
| Rhythm Pharmaceuticals, Inc. | 68.12 Million USD | 88.248% |
| Nuvalent, Inc. | - USD | -Infinity% |
| ABVC BioPharma, Inc. | -149.6 Thousand USD | 5451.354% |
| Carisma Therapeutics, Inc. | -59.2 Million USD | 113.522% |
| Unicycive Therapeutics, Inc. | 391 Thousand USD | -1947.57% |
| OmniAb, Inc. | 14.66 Million USD | 45.415% |
| Anew Medical, Inc. | - USD | -Infinity% |
| Fennec Pharmaceuticals Inc. | 19.99 Million USD | 59.956% |
| Lipocine Inc. | -2.85 Million USD | 380.832% |
| Lexeo Therapeutics, Inc. Common Stock | -1.84 Million USD | 534.4% |
| Nautilus Biotechnology, Inc. | -5.7 Million USD | 240.333% |
| SAB Biotherapeutics, Inc. | -1.5 Million USD | 631.504% |
| G1 Therapeutics, Inc. | 75.31 Million USD | 89.37% |
| Bellerophon Therapeutics, Inc. | -65 Thousand USD | 12416.923% |
| Sage Therapeutics, Inc. | 84.29 Million USD | 90.503% |
| Ocugen, Inc. | -33.53 Million USD | 123.872% |
| Mind Medicine (MindMed) Inc. | -3.16 Million USD | 353.194% |
| Q32 Bio Inc. | 578 Thousand USD | -1285.121% |
| Brainstorm Cell Therapeutics Inc. | -265 Thousand USD | 3121.132% |
| Alumis Inc. Common Stock | -1.28 Million USD | 723.52% |
| Equillium, Inc. | 35.95 Million USD | 77.735% |
| Kyverna Therapeutics, Inc. | -1.7 Million USD | 569.01% |
| Coya Therapeutics, Inc. | 500.67 Thousand USD | -1499.029% |
| CNS Pharmaceuticals, Inc. | -4134.00 USD | 193762.313% |
| Galera Therapeutics, Inc. | -259 Thousand USD | 3191.12% |
| Evelo Biosciences, Inc. | - USD | -Infinity% |
| Comera Life Sciences Holdings, Inc. | 422.71 Thousand USD | -1793.961% |
| Dominari Holdings Inc. | 2.03 Million USD | -292.643% |
| Edesa Biotech, Inc. | -183.47 Thousand USD | 4463.632% |
| vTv Therapeutics Inc. | -13.59 Million USD | 158.889% |
| Bio-Techne Corporation | 773.07 Million USD | 98.964% |
| Agios Pharmaceuticals, Inc. | 17.31 Million USD | 53.773% |
| Harmony Biosciences Holdings, Inc. | 460.78 Million USD | 98.263% |
| Prelude Therapeutics Incorporated | -1.16 Million USD | 784.859% |
| Candel Therapeutics, Inc. | -23.98 Million USD | 133.386% |
| iTeos Therapeutics, Inc. | 11.69 Million USD | 31.555% |
| Nkarta, Inc. | -5.86 Million USD | 236.412% |
| BioCardia, Inc. | -7.24 Million USD | 210.443% |
| Iterum Therapeutics plc | -1.75 Million USD | 557.486% |